158 related articles for article (PubMed ID: 21552143)
1. Continuing response to subsequent treatment lines with tyrosine kinase inhibitors in an adolescent with metastatic renal cell carcinoma.
De Pasquale MD; Pessolano R; Boldrini R; Ilari I; Donfrancesco A; Cortesi E; Jenkner A
J Pediatr Hematol Oncol; 2011 Jul; 33(5):e176-9. PubMed ID: 21552143
[TBL] [Abstract][Full Text] [Related]
2. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Jäger E; Jakse G; Wirth M; Keilholz U;
Aktuelle Urol; 2009 Jan; 40(1):27-30. PubMed ID: 19177318
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.
Hainsworth JD; Spigel DR; Burris HA; Waterhouse D; Clark BL; Whorf R
J Clin Oncol; 2010 May; 28(13):2131-6. PubMed ID: 20368560
[TBL] [Abstract][Full Text] [Related]
4. New therapeutic approaches in the management of metastatic renal cell carcinoma.
Gkialas IK; Papadopoulos G
J BUON; 2009; 14(3):399-404. PubMed ID: 19810129
[TBL] [Abstract][Full Text] [Related]
5. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
Margulis V; Matin SF; Tannir N; Tamboli P; Swanson DA; Jonasch E; Wood CG
J Urol; 2008 Jul; 180(1):94-8. PubMed ID: 18485389
[TBL] [Abstract][Full Text] [Related]
6. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy.
Amin C; Wallen E; Pruthi RS; Calvo BF; Godley PA; Rathmell WK
Urology; 2008 Oct; 72(4):864-8. PubMed ID: 18684493
[TBL] [Abstract][Full Text] [Related]
7. Systemic therapy for metastatic renal cell carcinoma.
Kroog GS; Motzer RJ
Urol Clin North Am; 2008 Nov; 35(4):687-701; ix. PubMed ID: 18992622
[TBL] [Abstract][Full Text] [Related]
8. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
Harzstark AL; Small EJ; Weinberg VK; Sun J; Ryan CJ; Lin AM; Fong L; Brocks DR; Rosenberg JE
Cancer; 2011 Sep; 117(18):4194-200. PubMed ID: 21387258
[TBL] [Abstract][Full Text] [Related]
9. [Renal cell carcinoma management and therapies in 2010].
Albouy B; Gross Goupil M; Escudier B; Massard C
Bull Cancer; 2010; 97():17-28. PubMed ID: 20418201
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant therapy with sorafenib in bone metastases bilateral renal carcinoma: a case report.
Sciarra A; Autran Gomez AM; Gentilucci A; Parente U; Salciccia S; Gentile V; Di Silverio F
Eur Urol; 2007 Aug; 52(2):597-9. PubMed ID: 17420088
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies.
Chowdhury S; Larkin JM; Gore ME
Eur J Cancer; 2008 Oct; 44(15):2152-61. PubMed ID: 18829302
[TBL] [Abstract][Full Text] [Related]
12. Trials probe new agents for kidney cancer.
Hampton T
JAMA; 2006 Jul; 296(2):155-7. PubMed ID: 16835411
[No Abstract] [Full Text] [Related]
13. [Treatment of locally advanced renal tumors].
Sánchez Zalabardo D; Millán Serrano JA; De Pablo Cárdenas A; Cuesta Alcalá JA
Actas Urol Esp; 2010 Feb; 34(2):134-41. PubMed ID: 20403277
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib rechallenge in patients with metastatic renal cell carcinoma.
Nozawa M; Yamamoto Y; Minami T; Shimizu N; Hatanaka Y; Tsuji H; Uemura H
BJU Int; 2012 Sep; 110(6 Pt B):E228-34. PubMed ID: 22332735
[TBL] [Abstract][Full Text] [Related]
15. Downsizing a thrombus of advanced renal cell carcinoma in a presurgical setting with sorafenib.
Takeda H; Nakano Y; Kashiwagi Y; Yoshino Y; Gotoh M
Urol Int; 2012; 88(2):235-7. PubMed ID: 22179282
[TBL] [Abstract][Full Text] [Related]
16. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
Wong MK; Jarkowski A
Pharmacotherapy; 2009 Apr; 29(4):473-8. PubMed ID: 19323623
[TBL] [Abstract][Full Text] [Related]
17. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.
Hainsworth JD; Sosman JA; Spigel DR; Edwards DL; Baughman C; Greco A
J Clin Oncol; 2005 Nov; 23(31):7889-96. PubMed ID: 16204015
[TBL] [Abstract][Full Text] [Related]
18. Temsirolimus in metastatic chromophobe renal cell carcinoma after interferon and sorafenib therapy.
Paule B; Brion N
Anticancer Res; 2011 Jan; 31(1):331-3. PubMed ID: 21273619
[TBL] [Abstract][Full Text] [Related]
19. Exploring the role of novel agents in the treatment of renal cell carcinoma.
Maluf FC; Fernandes Gdos S; Kann AG; Aguilar-Ponce JL; de la Garza J; Buzaid AC
Cancer Treat Rev; 2008 Dec; 34(8):750-60. PubMed ID: 18801619
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib.
Casciano R; Chulikavit M; Di Lorenzo G; Liu Z; Baladi JF; Wang X; Robertson J; Garrison L
Value Health; 2011; 14(6):846-51. PubMed ID: 21914504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
